EPH Receptor/ephrin System: in the Quest for Novel Anti-angiogenic Therapies: Commentary on Hassan-Mohamed Et al., Br J Pharmacol 171: 5195-5208

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2014 Apr 15

PMID 24724581

Citations 2

Authors

M Hatziapostolou

C Polytarchou

Affiliations

Soon will be listed here.

Abstract

This article is a Commentary on Hassan-Mohamed I, Giorgio C, Incerti M, Russo S, Pala D, Pasquale EB, Zanotti I, Vicini P, Barocelli E, Rivara S, Mor M, Lodola A and Tognolini M (2014). UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. Br J Pharmacol 171: 5195-5208. doi: 10.1111/bph.12669.

Citing Articles

Pathogenesis of Port-Wine Stains: Directions for Future Therapies.

Liu L, Li X, Zhao Q, Yang L, Jiang X Int J Mol Sci. 2022; 23(20).

PMID: 36292993 PMC: 9603382. DOI: 10.3390/ijms232012139.

Structural Analysis of the Binding of Type I, I1/2, and II Inhibitors to Eph Tyrosine Kinases.

Dong J, Zhao H, Zhou T, Spiliotopoulos D, Rajendran C, Li X ACS Med Chem Lett. 2015; 6(1):79-83.

PMID: 25589935 PMC: 4291711. DOI: 10.1021/ml500355x.

References

Boyd A, Bartlett P, Lackmann M . Therapeutic targeting of EPH receptors and their ligands. Nat Rev Drug Discov. 2014; 13(1):39-62. DOI: 10.1038/nrd4175. View

Moreno Garcia V, Basu B, Molife L, Kaye S . Combining antiangiogenics to overcome resistance: rationale and clinical experience. Clin Cancer Res. 2012; 18(14):3750-61. DOI: 10.1158/1078-0432.CCR-11-1275. View

Chen J, Hicks D, Brantley-Sieders D, Cheng N, McCollum G, Qi-Werdich X . Inhibition of retinal neovascularization by soluble EphA2 receptor. Exp Eye Res. 2005; 82(4):664-73. DOI: 10.1016/j.exer.2005.09.004. View

Noren N, Pasquale E . Paradoxes of the EphB4 receptor in cancer. Cancer Res. 2007; 67(9):3994-7. DOI: 10.1158/0008-5472.CAN-07-0525. View

Folkman J . Angiogenesis: an organizing principle for drug discovery?. Nat Rev Drug Discov. 2007; 6(4):273-86. DOI: 10.1038/nrd2115. View

Goel H, Mercurio A . VEGF targets the tumour cell. Nat Rev Cancer. 2013; 13(12):871-82. PMC: 4011842. DOI: 10.1038/nrc3627. View

Pasquale E . Eph-ephrin bidirectional signaling in physiology and disease. Cell. 2008; 133(1):38-52. DOI: 10.1016/j.cell.2008.03.011. View

Hassan-Mohamed I, Giorgio C, Incerti M, Russo S, Pala D, Pasquale E . UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. Br J Pharmacol. 2014; 171(23):5195-208. PMC: 4294034. DOI: 10.1111/bph.12669. View

Alexander S, Benson H, Faccenda E, Pawson A, Sharman J, Spedding M . The Concise Guide to PHARMACOLOGY 2013/14: catalytic receptors. Br J Pharmacol. 2014; 170(8):1676-705. PMC: 3892291. DOI: 10.1111/bph.12449. View

10.

Sawamiphak S, Seidel S, Essmann C, Wilkinson G, Pitulescu M, Acker T . Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature. 2010; 465(7297):487-91. DOI: 10.1038/nature08995. View

11.

Mosch B, Reissenweber B, Neuber C, Pietzsch J . Eph receptors and ephrin ligands: important players in angiogenesis and tumor angiogenesis. J Oncol. 2010; 2010:135285. PMC: 2836134. DOI: 10.1155/2010/135285. View